/PRNewswire/ Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to.
/PRNewswire/ REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium,.
Rise in prevalence of malnutrition, faster response time, and high efficacy associated with intravenous solution therapy have boosted the growth of the global intravenous solutions market. PORTLAND